Our top pick for
Beginners

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Hepion Pharmaceuticals, Inc is a biotechnology business based in the US. Hepion Pharmaceuticals shares (HEPA) are listed on the NASDAQ and all prices are listed in US Dollars. Hepion Pharmaceuticals employs 12 staff and has a market cap (total outstanding shares value) of USD$69.5 million.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Mobile users
Latest market close | USD$2.18 |
---|---|
52-week range | USD$1 - USD$6.9 |
50-day moving average | USD$2.1447 |
200-day moving average | USD$3.0519 |
Wall St. target price | USD$10 |
PE ratio | 0.3728 |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | USD$-50.579 |
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.18 from 2021-01-11
1 week (2021-01-11) | 2.18 |
---|---|
1 month (2020-12-18) | 12.37% |
3 months (2020-10-16) | -36.26% |
6 months (2020-07-17) | -41.08% |
1 year (2020-01-17) | -62.02% |
---|---|
2 years (2019-01-18) | 550.75% |
3 years (2018-01-18) | 587.70% |
5 years (2016-01-15) | 118.00% |
Valuing Hepion Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Hepion Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Hepion Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 0x. In other words, Hepion Pharmaceuticals shares trade at around 0x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Gross profit TTM | USD$0 |
---|---|
Return on assets TTM | -52.6% |
Return on equity TTM | -118.85% |
Profit margin | 0% |
Book value | $4.201 |
Market capitalisation | USD$69.5 million |
TTM: trailing 12 months
There are currently 203,488 Hepion Pharmaceuticals shares held short by investors – that's known as Hepion Pharmaceuticals's "short interest". This figure is 43.4% down from 359,445 last month.
There are a few different ways that this level of interest in shorting Hepion Pharmaceuticals shares can be evaluated.
Hepion Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Hepion Pharmaceuticals shares currently shorted divided by the average quantity of Hepion Pharmaceuticals shares traded daily (recently around 3.4 million). Hepion Pharmaceuticals's SIR currently stands at 0.06. In other words for every 100,000 Hepion Pharmaceuticals shares traded daily on the market, roughly 60 shares are currently held short.
However Hepion Pharmaceuticals's short interest can also be evaluated against the total number of Hepion Pharmaceuticals shares, or, against the total number of tradable Hepion Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Hepion Pharmaceuticals's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Hepion Pharmaceuticals shares in existence, roughly 10 shares are currently held short) or 0.0064% of the tradable shares (for every 100,000 tradable Hepion Pharmaceuticals shares, roughly 6 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Hepion Pharmaceuticals.
Find out more about how you can short Hepion Pharmaceuticals stock.
We're not expecting Hepion Pharmaceuticals to pay a dividend over the next 12 months.
Hepion Pharmaceuticals's shares were split on a 1:70 basis on 3 June 2019. So if you had owned 70 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Hepion Pharmaceuticals shares – just the quantity. However, indirectly, the new 6900% higher share price could have impacted the market appetite for Hepion Pharmaceuticals shares which in turn could have impacted Hepion Pharmaceuticals's share price.
Over the last 12 months, Hepion Pharmaceuticals's shares have ranged in value from as little as $1 up to $6.9. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Hepion Pharmaceuticals's is 1.4509. This would suggest that Hepion Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of pleiotropic drug therapy for the treatment of chronic liver diseases in the United States. It is involved in developing CRV431, a cyclophilin inhibitor that has completed the Phase I clinical trials for multiple biochemical pathways involved in the progression of liver diseases; and Tenofovir exalidex, a lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir diphosphate for the treatment of Hepatitis B. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.
Everything we know about the Bakkt Holdings IPO, plus information on how to buy in.
Everything we know about the Dream Finders Homes Inc IPO, plus information on how to buy in.
Everything we know about the Q BioMed Inc IPO, plus information on how to buy in.
Everything we know about the Faraday Future IPO, plus information on how to buy in.
Everything we know about the TELUS International Inc IPO, plus information on how to buy in.
Everything we know about the Interior Logic Group Holdings LLC IPO, plus information on how to buy in.
Everything we know about the Evaxion Biotech IPO, plus information on how to buy in.
Everything we know about the ON24 Inc IPO, plus information on how to buy in.
Everything we know about the Home Point Capital Inc IPO, plus information on how to buy in.
Everything we know about the ALFI INC IPO, plus information on how to buy in.